California's Life Science Industry Faces Policy Crossroads as Economic Impact Hits $394 Billion
核心洞察
California's life science sector generated $394 billion in economic output and supported over 1.08 million jobs in 2025, according to Biocom (搜索)'s 2026 Economic Impact Report.
The state budget imposed a permanent cap on R&D tax credits after 2030, a move industry leaders warn threatens California's long-standing leadership in biomedical innovation.
China's biotech sector has grown 400-fold over the past decade and now represents 40% of global drug development, compared to 35% from the United States.
California's life science industry generated $394 billion in total economic output and supported more than 1.08 million jobs statewide in 2025, even as the sector confronts mounting policy headwinds that industry leaders warn could erode the state's half-century of biomedical leadership.
The findings come from Biocom (搜索)'s 2026 Life Science Economic Impact Report, released in partnership with UC San Diego and HSBC Innovation Banking (搜索), which paints a picture of an industry that remains economically formidable while facing unprecedented challenges from both domestic policy shifts and intensifying global competition.
More than 406,000 Californians were directly employed in the life science industry, earning an average annual salary of $192,179. Life science organizations generated $65.2 billion in direct labor income and supported $126.9 billion in total labor income across the state. California companies attracted $73.1 billion in private investment, including $20.6 billion in venture capital funding, and the state remained the nation's largest recipient of NIH and NSF funding, securing $6.26 billion in research support through 9,486 awards.
"The life science industry in California has always been defined by its ability to innovate through uncertainty," said Tim Scott, president and CEO of Biocom (搜索). "Even as companies faced funding pressures, regulatory complexity and increased global competition, they continued to advance breakthrough science, invest in manufacturing, embrace new technologies and create opportunities for patients."
R&D Tax Credit Cap Sparks Industry Alarm
The release of the economic impact report coincides with a contentious policy decision in Sacramento. The state legislature passed a budget that imposes a permanent cap on R&D tax credits after 2030, a move that California Life Sciences (搜索) has characterized as a "shocking and disheartening development" for a state that calls itself the birthplace of biotech.
California's R&D tax credit has long been considered the primary state-level incentive encouraging life science investment. The life sciences sector, as the second largest industry in California, is among the most aggressive users of the credit because companies spend billions annually on researchers, scientists, and the capital-intensive work of drug development.
This decision came just ahead of the BIO International Convention in San Diego, where governors from other states routinely recruit biotech companies by promoting their own incentive programs. "Instead of defending our turf and this home-grown industry, Sacramento's recent decision makes our top-notch talent and incredibly productive innovation infrastructure open game for others to pick off for generations to come," California Life Sciences (搜索) stated.
Global Competition Intensifies
The policy shift unfolds against a backdrop of rapidly accelerating global competition, particularly from China. China's biotech sector has grown 400-fold over the past decade, and projections indicate China will outspend the United States on R&D by more than 50 percent by 2030. Some reports now show China as the global leader in drug development, representing 40% of all global drug development compared to 35% from the United States.
Investor funding that once defaulted to California's biotech start-up community is increasingly flowing to China, where regulatory timelines are shorter and biomedical dominance has been made an explicit national priority.
Warning Signs in the Data
California Life Sciences (搜索)' 2026 sector report reveals emerging red flags: for the first time, the state's major life sciences regions experienced consecutive years of employment loss, and San Diego saw a staggering 34% drop-off in venture capital funding for start-up biotechs.
Despite these pressures, the Biocom (搜索) report notes that the number of life science establishments grew to 15,730, an increase of nearly 2% year over year. Life science manufacturing employed 143,572 Californians and accounted for more than one-third of all life science jobs in the state. Companies continued to launch new ventures, expand manufacturing operations, and advance research programs.
"Behind every statistic in this report are researchers, entrepreneurs, manufacturers and innovators working to solve some of the world's most pressing health challenges," Scott said. "Together, they demonstrate why California remains the world's leading center for life science innovation and why continued investment in science matters."
The report also introduces The Ripple Effect, a collection of stories showcasing how Biocom (搜索) member companies are translating scientific discoveries into real-world impact, from breakthrough therapies and diagnostics to advanced manufacturing and emerging technologies. It further examines the growing role of artificial intelligence in drug discovery and manufacturing, evolving investment and licensing strategies, and the policy decisions influencing U.S. competitiveness in an increasingly global innovation landscape.